Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

642 results

• Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 979NCT04028492
• Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 240NCT04601272
• Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 3NCT04850313
• Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 30NCT01269372
• Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3):…Phase 2Results postedn = 171NCT03912532
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 67NCT05882357
• Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 158NCT04551014
• Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 506NCT00684671
• Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 9NCT02392494
• Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 185NCT00704717
• Evaluation of Reactogenicity and Safety of GSK Biologicals’ Rotarix™ (Human Rotavirus Vaccine) in Infants: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 522NCT00779779
• Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05019742).Phase 2Results postedn = 3NCT05019742
• Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 30NCT01943110
• Evaluation of the Rectal Reflex Using Anal Acoustic Reflectometry: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Rectal Reflex Using Anal Acoustic Reflectometry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02782377).Phase NAResults postedn = 40NCT02782377
• Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 87NCT02766777
• Evaluations of Alcohol Warning Labels: Complete Statistical AnalysisIndependent statistical analysis of Evaluations of Alcohol Warning Labels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06129487).Phase NAResults postedn = 1,053NCT06129487
• Exercise for Swallowing Problems After Stroke: Complete Statistical AnalysisIndependent statistical analysis of Exercise for Swallowing Problems After Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00722111).Phase NAResults postedn = 83NCT00722111
• Expiratory Muscle Training in Stroke: Complete Statistical AnalysisIndependent statistical analysis of Expiratory Muscle Training in Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04569968).Phase NAResults postedn = 146NCT04569968
• Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 5NCT02301377
• Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 331NCT02743806
• Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 12NCT02738008
• Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 2NCT02244944
• Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation: Complete Statistical AnalysisIndependent statistical analysis of Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04683744).Phase NAResults postedn = 82NCT04683744
• FANG-CLMIndependent statistical analysis of Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 3NCT01505166
• FAPESTIndependent statistical analysis of A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 92NCT01187901
• Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection: Complete Statistical AnalysisIndependent statistical analysis of Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00606944).Phase NAResults postedn = 200NCT00606944
• Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 3NCT05911243
• Feasibility Study of GlaxoSmithKline Biologicals’ GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 16NCT00871741
• FEAStIndependent statistical analysis of Fostering Eating After Stroke With Transcranial Direct Current Stimulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01919112).Phase NAResults postedn = 42NCT01919112
• Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn’s Colitis: Complete Statistical AnalysisIndependent statistical analysis of Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 15NCT02330653
• FEM-PrEPIndependent statistical analysis of FEM-PrEP, a randomized phase 3 trial evaluating Truvada versus placebo for preventing HIV acquisition in women, including its time-to-event analysis, safety endpoints, secondary outcomes, and statistical interpretation.Phase 3Results postedn = 2,120NCT00625404
• FIGARO UC 303Independent statistical analysis of An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 366NCT03290781
• Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study: Complete Statistical AnalysisIndependent statistical analysis of Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01285362).Phase NAResults postedn = 8NCT01285362
• Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2/3Results postedn = 2NCT01259284
• Flatbush FHC Proactive Colorectal Cancer Screening and Navigation: Complete Statistical AnalysisIndependent statistical analysis of Flatbush FHC Proactive Colorectal Cancer Screening and Navigation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05646355).Phase NAResults postedn = 109NCT05646355
• Fluorescent Evaluation of Colorectal Anastamoses: Complete Statistical AnalysisIndependent statistical analysis of Fluorescent Evaluation of Colorectal Anastamoses: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01424293).Phase NAResults postedn = 7NCT01424293
• FMT for FIIndependent statistical analysis of Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 10NCT04201821
• FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01688336).Phase 2Results postedn = 9NCT01688336
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138124).Phase NAResults postedn = 54,202NCT01138124
• Gastric pH and Anthocyanin Absorption: Complete Statistical AnalysisIndependent statistical analysis of Gastric pH and Anthocyanin Absorption: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01122160).Phase NAResults postedn = 13NCT01122160
• Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide: Complete Statistical AnalysisIndependent statistical analysis of Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 72NCT05033041
• Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170870).Phase 2Results postedn = 104NCT02170870
• GATEWAYIndependent statistical analysis of A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 4NCT04537377
• Gemcabene for the Treatment of Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Gemcabene for the Treatment of Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436420).Phase 2Results postedn = 6NCT03436420
• Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 123NCT00733746
• Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 10NCT00276861
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 83NCT01585805
• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 118NCT01064622
• Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).Phase 2Results postedn = 44NCT01459614
• GEMINI LTSIndependent statistical analysis of An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 2,243NCT00790933

← All therapeutic areas